Psilocin mucate
AssigneeLobe Sciences Ltd.
InventorsYousry Sayed, Frederick Sancilio, Philip J. Young, Shaileshkumar Ramanlal Desai, Autumn Beauchamp
Life of this patent
Estimating the term…
Abstract
Psilocin formulations of psilocin mucate with improved stability, physical properties and/or handling characteristics, as well as enhanced pharmacologic activity, pharmacokinetic parameters and safety characteristics as compared to psilocin or psilocybin and methods for their use are provided.
Claims20
A psilocin formulation comprising psilocin mucate, said formulation exhibiting:
- at least 95% bioavailability of psilocin;
- and/or
- at least twice the bioavailability of an equal amount of psilocin generated by metabolism of psilocybin;
- and/or
- no food effect upon oral administration;
- and/or
- at least a 2-fold decrease in time to maximum concentration (Tmax) as compared to an equivalent formulation of psilocybin.
An oral psilocin formulation comprising psilocin mucate which upon oral ingestion delivers concentrations of psilocin equal to intravenous administration of equivalent dose of psilocybin to a subject.
A method for producing a psilocin salt with stability for 12 or more months, said method comprising mixing psilocin with galactaric acid (mucic acid).
Dependencies are inferred from the claim text.